| Basics |
Kala Pharmaceuticals, Inc.
Kala Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary nanoparticle-based Mucus Penetrating Particles technology, with focus on the treatment of eye diseases.
|
| IPO Date: |
July 20, 2017 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$7.39M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.31 | 3.78%
|
| Avg Daily Range (30 D): |
$0.05 | 5.46%
|
| Avg Daily Range (90 D): |
$0.36 | 5.86%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.84M |
| Avg Daily Volume (30 D): |
10.64M |
| Avg Daily Volume (90 D): |
4.25M |
| Trade Size |
| Avg Trade Size (Sh.): |
199 |
| Avg Trade Size (Sh.) (30 D): |
369 |
| Avg Trade Size (Sh.) (90 D): |
328 |
| Institutional Trades |
| Total Inst.Trades: |
195 |
| Avg Inst. Trade: |
$1.54M |
| Avg Inst. Trade (30 D): |
$.59M |
| Avg Inst. Trade (90 D): |
$.54M |
| Avg Inst. Trade Volume: |
.02M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.4M |
| Avg Closing Trade (30 D): |
$.59M |
| Avg Closing Trade (90 D): |
$.59M |
| Avg Closing Volume: |
7.21K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$-5.64
|
$-1.07
|
$-1.71
|
|
Diluted EPS
|
$-5.64
|
$-1.07
|
$-1.71
|
|
Revenue
|
$ M
|
$ M
|
$ M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -35.84M
|
$ -7.56M
|
$ -11.16M
|
|
Operating Income / Loss
|
$ -38.4M
|
$ -7.24M
|
$ -11.03M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -28.11M
|
$ -10.85M
|
$ -16.56M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Oct 21, 2022:
1:50
|
|
Aug 26, 2022:
1.00:1
|
|
|
|
